Date: 2014-10-28
Type of information: Fundraising
Company: Advent Life Sciences (UK)
Investors:
Amount: £145.5 million (€184.7 million)
Funding type: fundraising
Planned used: The new fund will be used to seed and build life sciences companies in the UK, Europe and the US. It will back entrepreneurs and early-stage and mid-stage companies with the potential to deliver first- or best-in-class breakthrough products for unmet medical needs.
Others: * On October 28 2014, Advent Life Sciences announced the closing of Advent Life Sciences Fund II (ALSF II), a £145.5M (USD 235M) venture capital fund raised to seed and build life sciences companies in the UK, Europe and the US. The Fund, which quickly exceeded its target, was raised entirely from independent financial investors including funds-of-funds, pension funds, and family offices.
Therapeutic area:
